J&J's Analgesic Sales Ease Pain Of Ongoing OTC Turnaround
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
CFO Dominic Caruso reaffirms J&J’s commitment to keeping and growing its consumer business as the firm reports its OTC adult analgesic US market share reached 14% while pediatric share was nearly 46%.